Highlights for the quarter ending 30 September 2018:
• Customer receipts for the first quarter of FY2019 at $2.01 million, up 100% from thesame period in FY2018 ($1.01 million)
• Consumer health sales at $1.55 million for the quarter, up 50% compared with $1.03million in the same period in FY2018 ]
• Successful US retail store launch with experiential marketing events in 13 locations
• Positive preclinical results for midkine antibody (CAB102) in FSGS towards orphan drugapplication
SYDNEY, Monday, 15 October 2018: Cellmid Limited (ASX: CDY) provides thefollowing notes to its Appendix 4C Quarterly Cash Flow report for the first quarter ofthe 2019 financial year (Q1 FY2019).Customer receipts from sales reached $2.01 million for Q1 FY2019, which represents a100% increase on receipts for the same period last year (Q1 FY2018: $1.01 million).
Consumer health sales for Q1 FY2019 were up 50% at $1.55 million compared with thesame period in FY2018 (Q1 FY2018: $1.03 million).Sales in all three geographies (Australia, Japan and USA) grew compared with thesame period last year. The USA recorded the highest growth rate, while Japancontinues to represent the largest amount in terms of sales revenue.
Cash balance at the end of the quarter was $9.26 million, up from the $1.61 million atthe end of the previous quarter. Following the successful completion of the $10.03million (ex-costs) private placement and share purchase plan in September 2018 theCompany repaid $1.00 million of the $2.00 million Platinum Road R&D loan facilityduring the quarter.
The remaining $1.00 million is expected to be repaid with interestin 2Q FY2019.Other significant cash outflows related to inventory manufacture, which was $1.16million compared with $179K in the same period in FY2018 to service anticipatedsales growth.
